Shares of the commercial-stage biotechnology company, Krystal Biotech, Inc. (KRYS) , surged 36.5% year to date against the industry’s decline of 4.3%. This was due to the strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress. In May 2023, the FDA approved Vyjuvek, the first ever redosable gene therapy for treating patients aged six months or older with dystrophic epidermolysis bullosa (DEB). DEB is a rare and severe monogenic disease that affects the skin and mucosal tissues. It ...